Human Antibody-enabled Cardiovascular Personalized Theranosis
ABCardionostics envisions an innovative multi-marker-based positron emission tomography (PET)/ magnetic resonance imaging (MRI) system for efficient staging and personalized treatment of vulnerable patients with atherosclerosis. T...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
EQC2019-006485-P
RENOVACIÓN PLATAFORMA IMAGEN MOLECULAR MS-IMAGING DE LA UNID...
592K€
Cerrado
TED2021-129774B-C22
CORAZON DIGITAL: NUEVAS HERRAMIENTAS Y MODELOS BASADOS EN CF...
234K€
Cerrado
PDC2021-121424-I00
BIOPSIA Y TEJIDO EN UN CHIP MAS BIOSENSORES MULTIPLEXADOS IN...
138K€
Cerrado
HYPMET
Hyperpolarized Magnetic Resonance at the point-of-care
1M€
Cerrado
LUMABS
Therapeutic antibody drug monitoring using bioluminescent se...
150K€
Cerrado
Cellularity
The critical shift to single-cell formats in functional anal...
5M€
Cerrado
Información proyecto ABCardionostics
Duración del proyecto: 49 meses
Fecha Inicio: 2024-02-29
Fecha Fin: 2028-03-31
Líder del proyecto
UNIVERSITE DE BORDEAUX
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
ABCardionostics envisions an innovative multi-marker-based positron emission tomography (PET)/ magnetic resonance imaging (MRI) system for efficient staging and personalized treatment of vulnerable patients with atherosclerosis. To provide a snapshot of plaque composition, along the arterial tree of at-risk patients, human antibodies (HuAbs) targeting different affected arterial sites will be developed. Importantly, HuAbs targeting culprit and protective monocyte/macrophage (MoMP) populations that are instrumental in plaque progression will be crucial to assess disease status and reprogramme an unbalanced functional state toward atheroprotection. To translate this concept into clinical practice, the ABCardionostics consortium will combine cutting-edge biotechnologies and in silico and computing analyses to close the knowledge gaps on plaque MoMP spatiotemporal dynamics and the lack of imaging approaches for multi-marker detection: pioneering in vivo and in vitro phage display approaches to identify relevant HuAbs (UBx), multispectral mapping and MacroScreen to unravel the functionomics of MoMP subsets in atherosclerosis (MUNC), unvisited in silico and biochip development to identify HuAb targets (MAbS, CNRS-TBI), innovative HuAb bioengineering techniques (CNRS-BacFly, and UBx-INP, BTM), derivatization and labelling to develop PET tracers to finally explore the feasibility of a translational non-invasive multi-marker PET/MRI system for diagnosis and monitoring (CNIC) and an adapted immunotherapy strategy targeted to the appropriate plaque by designing bispecific antibodies (CNRS-BacFly). Data processing will integrate multimodal images to obtain insight into plaque morphology and composition (PMI). ABCardionostics successful completion will bring HuAb leads for atherosclerosis theranosis, and novel tools for HuAb identification and design, easily transposable to other diseases, revolutionizing the current imaging and therapeutic approaches.